

Association Between Nonsteroidal Anti-inflammatory Drugs Use and Surgical Outcomes Following Posterior Lumbar Fusion: A Medical Claims Database Analysis

Aneysis D. Gonzalez-Suarez, Allen Green, María José Cavagnaro, Emily Moya, Corinna Zygorakis and Atman M. Desai

Int J Spine Surg 2025, 19 (2) 224-236

doi: <https://doi.org/10.14444/8732>

<https://www.ijssurgery.com/content/19/2/224>

This information is current as of May 13, 2025.

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://ijssurgery.com/alerts>

Association Between Nonsteroidal Anti-inflammatory Drugs Use and Surgical Outcomes Following Posterior Lumbar Fusion: A Medical Claims Database Analysis

ANEYSIS D. GONZALEZ-SUAREZ, PhD¹; ALLEN GREEN, BS¹; MARÍA JOSÉ CAVAGNARO, MD²; EMILY MOYA, BA¹; CORINNA ZYGOURAKIS, MD²; AND ATMAN M. DESAI, MD²

¹Stanford University School of Medicine, Stanford, CA, USA; ²Department of Neurosurgery, Stanford University, Stanford, CA, USA

ABSTRACT

Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for postoperative pain management after spinal fusion surgeries, but their potential impact on fusion outcomes and wound healing remains controversial.

Objective: To use a national database and consistent selection criteria to compare the postoperative outcomes of patients who first received NSAIDs ≤ 72 hours, 72 hours to 90 days, and 90 days to 1 year after posterior lumbar fusion (PLF) surgery, to those who never received NSAIDs within the first year of surgery.

Methods: Using the Merative MarketScan Research Databases, we analyzed PLF patients aged 18 to 90 years who underwent either single- and multilevel fusions. A subanalysis focused specifically on single-level fusions. Using the inverse probability of treatment weighting to adjust for confounders, we compared the outcomes of patients first administered NSAIDs at 3 different postoperative timeframes (≤ 72 hours, 72 hours to 90 days, and 90 days to 1 year) to patients who did not receive NSAIDs within 1 year of surgery. The outcomes evaluated included 30-day readmissions, length of stay, pseudoarthrosis, hardware failure, and wound complications up to 1 year after surgery.

Results: Single- and multilevel PLF patients who received >90 -day courses of NSAIDs 72 hours to 1 year postoperatively had greater odds of pseudoarthrosis, with those receiving short, ≤ 30 -day courses of NSAIDs 72 hours to 90 days postoperatively additionally having greater odds of wound complications. Meanwhile, patients who started ≤ 30 -day courses of NSAIDs within 72 hours of surgery experienced reduced length of stay and lower rates of wound complications.

Conclusion: Administration of long courses of NSAIDs >72 hours to 1 year after PLF surgery is associated with higher odds of pseudoarthrosis, while short courses of NSAIDs administered 72 hours to 90 days of surgery are additionally associated with higher odds of wound complications. Conversely, patients who received NSAIDs within 72 hours of surgery may experience a slightly reduced length of hospital stay, with short courses of NSAIDs protecting against wound complications.

Clinical Relevance: This study suggests that the timing and duration of postoperative NSAID use after posterior lumbar fusion can significantly affect outcomes, particularly fusion integrity and wound healing. These findings may help guide pain management protocols to balance effective analgesia with minimizing surgical complications.

Level of Evidence: 3.

Lumbar Spine

Keywords: posterior lumbar fusion (PLF), non-steroidal anti-inflammatory drugs (NSAIDs), pseudoarthrosis, hardware failure, wound complications, readmissions

INTRODUCTION

Spinal fusion surgeries, such as posterior lumbar fusion (PLF), are vital interventions for a spectrum of spinal pathologies, including degenerative disc disease, scoliosis, spinal tumors, and trauma.^{1,2} Elective PLF, particularly for degenerative conditions, has seen a remarkable increase, surging by 62% in the United States from 2004 to 2015.² This upsurge has placed PLF among the most frequently performed surgeries in the country. However, the complexity of PLF surgeries brings about considerable risks and the potential for various postoperative complications that contribute

to increased health care costs.^{2–4} Given the prevalence of PLF surgeries, it is crucial for health care providers and patients alike to be well informed about the factors influencing adverse postoperative outcomes associated with PLF to ensure better prognostic outcomes and optimized care delivery.

Among these factors, nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for pain control, yet their use after spine surgery remains controversial. These medications inhibit cyclooxygenase, preventing the synthesis of prostaglandins, thromboxanes, and prostacyclins, thereby potentially impacting wound

and bone healing processes crucial for recovery.⁵⁻⁷ Research on the relationship between NSAID use and postoperative outcomes has yielded conflicting findings. Some studies have suggested unfavorable effects, such as reduced fracture healing rates leading to delayed union or nonunion.⁸⁻¹¹ In the context of wound healing, the NSAIDs-mediated suppression of PGE2 may enhance scar formation and lead to antiproliferation of blood vessels and skin, conceivably resulting in delayed healing.^{6,7} However, other studies have failed to establish a clear connection between NSAIDs and delayed wound or bone healing.¹²⁻¹⁴ These discrepancies between findings could be attributed to differences in study designs, including different NSAID dosages, administration timing, limited number of drugs, and uncontrolled confounding variables or patient characteristics. These studies have also typically explored outcomes within varying postoperative timeframes, posing challenges for direct comparisons and impacting the generalizability of results.

In the present study, we aimed to address some of these inconsistencies by leveraging a national database and maintaining uniform patient selection criteria to compare the postoperative outcomes across 3 different NSAID administration windows following PLF surgery. In addition to the commonly reported outcomes in the literature, such as nonunion, we additionally evaluated wound complications, hardware failure, 30-day readmissions, and length of stay (LOS). By doing so, we aimed to build on the current literature and provide an understanding of how NSAIDs used at different time windows after surgery are associated with different patient outcomes. To do this, we controlled for confounding patient comorbidities, such as diabetes and other baseline health conditions, to minimize bias and ensure a more accurate assessment of the associations observed. Additionally, we performed subanalyses to evaluate how these associations may differ between patients undergoing multilevel vs single-level fusions. We purposefully used a patient database that included individuals taking a wide variety of NSAIDs to gain a collective understanding of the drug class as a whole, rather than focusing on the effects of individual medications. This approach allowed us to isolate the potential effects of NSAID timing on postoperative outcomes.

METHODS

Data Source

The study utilized the Merative MarketScan Research Databases, a deidentified national database that spans

a wide array of health care settings and recorded data from >250 million patients, for a query on patients who underwent PLF between 2007 and 2022.¹⁵ Due to the deidentified nature of MarketScan, the study was deemed exempt from requiring approval by the Institutional Review Board of our university.

Cohort Selection

Patients aged 18 to 90 years who underwent PLF, defined with an arthrodesis current procedural terminology (CPT) code of 22612 or 22633 and an instrumentation code (i.e., 22840 or 22842 or 22843 or 22844), were selected. To qualify for the study and minimize attrition bias via inverse probability of treatment weighting (IPTW), subjects had to have ≥ 1 year of medical history with ≥ 1 -year follow-up. We excluded patients with a 1-year history of anterior arthrodesis (CPT 2258). Depending on whether variables were binary or continuous, missing data were addressed by assigning a zero for missing binary entries, signifying no diagnosis, while omissions in continuous variables were left out of the dataset. A subcohort analysis evaluated PLF patients undergoing uncomplicated, single-level fusions, excluding those with CPT codes 22842 and 22843.

Treatment Groups for Comparison

Patients were grouped based on NSAID administration during 3 postoperative periods: ≤ 72 hours after surgery, 72 hours to 90 days, and 90 days to 1 year postoperatively—all compared with patients who did not receive NSAIDs ≤ 1 year after surgery. NSAIDs were administered orally, with the exception of IV NSAIDs provided ≤ 72 hours postoperatively. Additionally, we analyzed how the length of NSAIDs courses (1–30, 31–90, 91–180, 181–365, and 366–720 days) impacted the postoperative outcomes measured, comparing these dispensation intervals within each NSAIDs administration group to the no NSAIDs control group. Figure 1 shows the frequency of NSAIDs types and the specific dosages prescribed during different length courses across the 3 postoperative timeframes, highlighting commonly used NSAIDs, such as meloxicam and Celecoxib, and how their usage patterns varied with both dosage and duration. Furthermore, Figure 2 provides a detailed overview of the cohort selection process, including the exclusion criteria and grouping of patients based on NSAID administration timing.




Figure 1. Distribution of nonsteroidal anti-inflammatory drug (NSAID) dispensation across postsurgical time intervals based on the timing of NSAID initiation. Heatmaps represent the distribution of NSAIDs dispensation across various time intervals postsurgery for different cohorts based on the timing of NSAIDs initiation. (A) NSAIDs started between 0 and 72 h of surgery with various day supply prescribed. (B) As in (A), but for patients who began NSAIDs between 72 h and 90 d postsurgery. (C) As in (A), but for patients who began NSAIDs between 90 d and 1 y postsurgery. The color intensity reflects the number of patients, with warmer colors indicating higher patient frequency and cooler colors indicating lower frequency. The x-axis shows the NSAIDs dispensation intervals (1–3 d, 4–7 d, 8–30 d, 31–90 d, 91–180 d, 181–365 d, 366–720 d), and the y-axis lists the specific NSAIDs and their dosages administered.




Figure 2. Selection criteria flow chart for the posterior lumbar fusion (PLF) cohort depicting the selection inclusion and exclusion criteria for the final PLF patients in the study.

Patient Characteristics

The burden of comorbidities within this patient cohort was evaluated by providing the prevalence and percentages of specific Charlson Comorbidity Index disorders within the NSAIDs or control groups. We defined gender as a binary variable and expressed it in terms of counts and percentages (ie, number and percentage of women). Age was treated as a continuous metric, expressed using mean and SD and also categorized by age groups to report patient counts and percentages. When the standardized mean differences (SMD) between the NSAIDs and the control group exceeded 0.25,¹⁶ patient characteristics, such as gender and age, were considered significantly different.

Postoperative Outcomes

Postoperative outcomes ≤ 1 year after surgery were analyzed, including all-cause, 30-day readmissions, LOS, pseudoarthrosis/nonunion, hardware failure, and wound complications—such as hemorrhage, hematoma, infection, and dehiscence. To ensure accurate outcome assessment, each was identified using a coding system consisting of CPT, ICD-9, and ICD-10 codes.

Statistical Analysis

Incidence rates of outcomes for treated vs control groups were compared through odds ratios and 95% confidence intervals from logistic regression using MATLAB software (v9.13.0 [R2023b], Natick, MA, USA). For the LOS in days, which are discrete counts, we utilized incidence rate ratios obtained from hurdle negative binomial regression. To maintain rigor in our statistical analysis, we accounted for multiple comparisons and outcomes assessed by using a Bonferroni-corrected $P \leq 0.01$.^{17–20}

Confounder Adjustment

To adjust for confounders, we used the IPTW approach, which is underpinned by high-dimensional propensity scores (hdPS) derived from baseline variables such as pretreatment diagnostic, procedure, and medication codes, as per the protocol detailed in Schneeweiss et al.²¹ The hdPS was designed to balance the baseline characteristics between our study's control and treatment groups, with each participant's weight being the inverse of their probability of receiving the treatment, thus fostering a balanced pseudopopulation.

and controlling for cofounders. Specifically, we adjusted for patient demographics (eg, age and gender) and a comprehensive range of comorbidities, including congestive heart failure, diabetes, chronic pulmonary disease, tumors, peripheral vascular disease, peptic ulcer disease, stroke, renal disease, dementia, liver disease, paralysis, rheumatoid arthritis, human immunodeficiency virus, and myocardial infarction. Logistic regression was utilized to fit a propensity score model incorporating these hdPS covariates, applying the Least Absolute Shrinkage and Selection Operator method to prune less significant variables. The fine-tuning of the Least Absolute Shrinkage and Selection Operator model, specifically the lambda hyperparameter, was accomplished through 5-fold crossvalidation based on the 1-standard error principle, aiming to forge a more parsimonious model without overfitting, as discussed in the literature.²²

RESULTS

Study Population Characteristics

In this study, 47,754 patients who were not administered NSAIDs were contrasted with those who were: 873 treated ≤ 72 hours, 10,526 within 72 hours to 90 days, and 13,633 between 90 days to 1 year after surgery. Baseline demographics and clinical profiles were similar among the groups: control, 54.12% women aged 52.01 ± 9.32 years; ≤ 72 hours group, 54.17% women aged 52.00 ± 9.32 years; 72 hours to 90 days group, 55.33% women aged 52.31 ± 9.15 years; 90 days to 1 year group 55.59% women aged 52.04 ± 9.25 years (Table 1). Diabetes was the most prevalent comorbidity among all 3 NSAIDs groups (control, 21.72%; ≤ 72 hours, 21.74%; 72 hours to 90 days, 22.41%; 90 days to 1 year, 21.72%). The most common administration course length was 31 to 365 days, with meloxicam 15 mg, celecoxib 200 mg, ibuprofen 800 mg, and naproxen 500 mg being the most commonly prescribed NSAIDs (Figure 1).

In a subanalysis of uncomplicated, single-level PLF patients, 27,101 patients did not receive NSAIDs, compared with 542 treated ≤ 72 hours, 5823 72 hours to 90 days and 7725 90 days to 1 year after surgery (Table 2). Baseline characteristics were similar to those of the combined single- and multilevel PLF cohort; control, 56.04% women aged 51.57 ± 9.31 years; ≤ 72 hours, 56.12% women aged 51.57 ± 9.31 years; 72 hours to 90 days, 57.19% women aged 51.84 ± 9.15 years; 90 days to 1 year 57.40% women aged 51.53 ± 9.28 years. The most prevalent comorbidity in this cohort was also

diabetes (control, 20.64%; ≤ 72 hours, 20.66%; 72 hours to 90 days, 21.36%; 90 days to 1 year, 20.65%).

Propensity Score-Matched Analysis

The balance achieved between the control and NSAIDs groups post-IPTW matching was evidenced by many SMD values falling below 0.25, across sex, age, and baseline comorbidities, suggesting the efficacy of IPTW in neutralizing a variety of confounders (Table 1) and further bolstered by using a Bonferroni-adjusted P value ≤ 0.01 (Table 3).

Control vs ≤ 72 Hours NSAIDs

Compared with the control group, PLF patients who received NSAIDs ≤ 72 hours postoperatively did not have significantly different 30-day readmissions (0.883 [0.631, 1.237], $P = 0.470$) or pseudoarthrosis/hardware failure outcomes (1.198 [1.020, 1.408], $P = 0.028$), at the Bonferroni-adjusted P value of 0.01. However, these patients did have lower associations with wound complications (0.692 [0.538, 0.889], $P = 0.004$), especially when prescribed ≤ 30 -day course of NSAIDs (0.571 [0.391, 0.832], $P = 0.004$; Table 4), and shorter LOS (0.736 [0.706, 0.768], $P < 0.001$). Findings were similar in patients who underwent uncomplicated, single-level PLF: no significant associations were found in readmissions (0.836 [0.506, 1.380], $P = 0.483$), pseudoarthrosis/hardware failure (1.068 [0.882, 1.294], $P = 0.500$), or with wound complications (0.839 [0.599, 1.175], $P = 0.308$; Table 5). However, this group did have significantly shorter LOS (0.757 [0.715, 0.801], $P < 0.001$).

Control vs 72 Hours to 90 Days NSAIDs

Patients who started NSAIDs use 72 hours to 90 days postoperatively did not have significant differences in 30-day readmissions (1.011 [0.962, 1.063], $P = 0.666$). However, these patients did have increased associations with wound complications (1.069 [1.035, 1.105], $P < 0.001$), especially when provided with short, ≤ 30 -day NSAIDs course (1.427, [1.286, 1.583], $P < 0.001$), and pseudoarthrosis/hardware failure (1.042 [1.017, 1.068], $P = 0.001$), particularly with longer, > 180 NSAIDs courses (1.212 [1.114, 1.317], $P < 0.001$; Table 6). Similarly, while the uncomplicated, single-level PLF cohort did not show a significant association with readmissions (1.029 [0.954, 1.109], $P = 0.462$; Table 5), pseudoarthrosis/hardware failure was significantly associated with NSAIDs use (1.048 [1.015, 1.082], $P = 0.004$), as were wound complications (1.150 [1.097, 1.206], $P < 0.001$).

Table 1. Demographics and clinical characteristics of PLF patients with NSAIDs use ≤ 72 h, 72 h to 90 d, or 90 d to 1 y after surgery.

Variable	NSAIDs ≤ 72 h					
	Before IPTW			After IPTW		
	Control	Intervention	SMD	Control	Intervention	SMD
Age, y, mean (SD)	52.01 (9.32)	52.00 (9.32)	0.063	52.01 (9.32)	51.42 (9.52)	0.010
Gender, woman, <i>n</i> (%)	25,844 (54.12%)	26,340 (54.17%)	0.054	25,844 (54.12%)	496 (56.82%)	0.001
Comorbidities, <i>n</i> (%)						
CHF	1612 (3.38%)	1636 (3.36%)	0.035	1612 (3.38%)	24 (2.75%)	0.008
Diabetes	10,372 (21.72%)	10,572 (21.74%)	0.029	10,372 (21.72%)	200 (22.91%)	0.001
CPD	6967 (14.59%)	7102 (14.61%)	0.025	6967 (14.59%)	135 (15.46%)	0.009
Tumors	93 (0.19%)	98 (0.20%)	0.084	93 (0.19%)	<11	0.001
PVD	2418 (5.06%)	2448 (5.03%)	0.074	2418 (5.06%)	30 (3.44%)	0.004
PUD	211 (0.44%)	214 (0.44%)	0.015	211 (0.44%)	<11	0.002
Stroke	697 (1.46%)	708 (1.46%)	0.017	697 (1.46%)	11 (1.26%)	0.002
Renal disease	567 (1.19%)	574 (1.18%)	0.036	567 (1.19%)	<11	0.003
Dementia	34 (0.07%)	37 (0.08%)	0.099	34 (0.07%)	<11	0.003
Liver disease	2552 (5.34%)	2605 (5.36%)	0.032	2552 (5.34%)	53 (6.07%)	0.005
Paralysis	452 (0.95%)	468 (0.96%)	0.091	452 (0.95%)	16 (1.83%)	0.004
Rheumatoid arthritis	2637 (5.52%)	2722 (5.60%)	0.183	2637 (5.52%)	85 (9.74%)	0.002
HIV	32 (0.07%)	34 (0.07%)	0.061	32 (0.07%)	<11	0.001
MI	146 (0.31%)	148 (0.30%)	0.014	146 (0.31%)	<11	0.004

Variable	NSAIDs 72 h to 90 d					
	Before IPTW			After IPTW		
	Control	Intervention	SMD	Control	Intervention	SMD
Age, y, mean (SD)	52.01 (9.32)	52.31 (9.15)	0.178	52.01 (9.32)	53.64 (8.20)	0.008
Gender, woman, <i>n</i> (%)	25,844 (54.12%)	32,247 (55.33%)	0.135	25,844 (54.12%)	6403 (60.83%)	0.001
Comorbidities, <i>n</i> (%)						
CHF	1612 (3.38%)	1988 (3.41%)	0.011	1612 (3.38%)	376 (3.57%)	0.005
Diabetes	10,372 (21.72%)	13,061 (22.41%)	0.092	10,372 (21.72%)	2689 (25.55%)	0.005
CPD	6967 (14.59%)	8792 (15.09%)	0.077	6967 (14.59%)	1825 (17.34%)	0.004
Tumors	93 (0.19%)	106 (0.18%)	0.017	93 (0.19%)	13 (0.12%)	0.000
PVD	2418 (5.06%)	3022 (5.19%)	0.030	2418 (5.06%)	604 (5.74%)	0.000
PUD	211 (0.44%)	269 (0.46%)	0.016	211 (0.44%)	58 (0.55%)	0.005
Stroke	697 (1.46%)	853 (1.46%)	0.002	697 (1.46%)	156 (1.48%)	0.004
Renal disease	567 (1.19%)	632 (1.08%)	0.055	567 (1.19%)	65 (0.62%)	0.012
Dementia	34 (0.07%)	42 (0.07%)	0.002	34 (0.07%)	<11	0.004
Liver disease	2552 (5.34%)	3198 (5.49%)	0.035	2552 (5.34%)	646 (6.14%)	0.004
Paralysis	452 (0.95%)	588 (1.01%)	0.035	452 (0.95%)	136 (1.29%)	0.000
Rheumatoid arthritis	2637 (5.52%)	3738 (6.41%)	0.202	2637 (5.52%)	1101 (10.46%)	0.001
HIV	32 (0.07%)	42 (0.07%)	0.010	32 (0.07%)	<11	0.003
MI	146 (0.31%)	187 (0.32%)	0.015	146 (0.31%)	41 (0.39%)	0.005

Variable	NSAIDs 90 d to 1 y					
	Before IPTW			After IPTW		
	Control	Intervention	SMD	Control	Intervention	SMD
Age, y, mean (SD)	52.01 (9.32)	52.04 (9.25)	0.016	52.01 (9.32)	52.16 (9.00)	0.002
Gender, man, <i>n</i> (%)	25,844 (54.12%)	34,125 (55.59%)	0.133	25,844 (54.12%)	8281 (60.74%)	0.000
Comorbidities, <i>n</i> (%)						
CHF	1612 (3.38%)	2062 (3.36%)	0.004	1612 (3.38%)	450 (3.30%)	0.000
Diabetes	10,372 (21.72%)	13,333 (21.72%)	0.000	10,372 (21.72%)	2961 (21.72%)	0.001
CPD	6967 (14.59%)	9219 (15.02%)	0.054	6967 (14.59%)	2252 (16.52%)	0.001
Tumors	93 (0.19%)	112 (0.18%)	0.013	93 (0.19%)	19 (0.14%)	0.000
PVD	2418 (5.06%)	3142 (5.12%)	0.011	2418 (5.06%)	724 (5.31%)	0.001
PUD	211 (0.44%)	281 (0.46%)	0.011	211 (0.44%)	70 (0.51%)	0.000
Stroke	697 (1.46%)	877 (1.43%)	0.012	697 (1.46%)	180 (1.32%)	0.001
Renal disease	567 (1.19%)	675 (1.10%)	0.038	567 (1.19%)	108 (0.79%)	0.002
Dementia	34 (0.07%)	47 (0.08%)	0.009	34 (0.07%)	13 (0.10%)	0.000
Liver disease	2552 (5.34%)	3404 (5.55%)	0.040	2552 (5.34%)	852 (6.25%)	0.000
Paralysis	452 (0.95%)	564 (0.92%)	0.013	452 (0.95%)	112 (0.82%)	0.001
Rheumatoid arthritis	2637 (5.52%)	3725 (6.07%)	0.103	2637 (5.52%)	1088 (7.98%)	0.001
HIV	32 (0.07%)	45 (0.07%)	0.010	32 (0.07%)	13 (0.10%)	0.000
MI	146 (0.31%)	180 (0.29%)	0.010	146 (0.31%)	34 (0.25%)	0.001

Abbreviations: CHF, congestive heart failure; CPD, chronic pulmonary disease; HIV, human immunodeficiency virus; IPTW, inverse probability of treatment weighting; MI, myocardial infarction; NSAIDs, nonsteroidal anti-inflammatory drugs; PLF, posterior lumbar fusion; PUD, peptic ulcer disease; PVD, peripheral vascular disease; SMD, standardized mean difference.

Note: Cells with fewer than 11 patients were not reported or inferred per the data use agreement.

Table 2. Demographics of patients who received NSAIDs after uncomplicated, single-level PLF surgery at 3 different time windows.

Variable	NSAIDs <72 h					
	Before IPTW			After IPTW		
	Control	Intervention	SMD	Control	Intervention	SMD
Age, y, mean (SD)	51.57 (9.31)	51.57 (9.31)	0.039	51.57 (9.31)	51.21 (9.28)	0.013
Gender, woman, <i>n</i> (%)	15,187 (56.04%)	15,513 (56.12%)	0.083	15,187 (56.04%)	326 (60.15%)	0.001
Comorbidities, <i>n</i> (%)						
CHF	884 (3.26%)	897 (3.24%)	0.049	884 (3.26%)	13 (2.40%)	0.000
Diabetes	5594 (20.64%)	5712 (20.66%)	0.028	5594 (20.64%)	118 (21.77%)	0.021
CPD	3907 (14.42%)	3988 (14.43%)	0.015	3907 (14.42%)	81 (14.94%)	0.015
Tumors	24 (0.09%)	28 (0.10%)	0.204	24 (0.09%)	14 (0.74%)	0.000
PVD	1338 (4.94%)	1355 (4.90%)	0.083	1338 (4.94%)	17 (3.14%)	0.013
PUD	132 (0.49%)	132 (0.48%)	0.071	132 (0.49%)	11 (0.06%)	0.070
Stroke	382 (1.41%)	390 (1.41%)	0.006	382 (1.41%)	18 (1.48%)	0.007
Renal disease	287 (1.06%)	288 (1.04%)	0.086	287 (1.06%)	11 (0.18%)	0.012
Dementia	21 (0.08%)	23 (0.08%)	0.101	21 (0.08%)	12 (0.37%)	0.012
Liver disease	1422 (5.25%)	1456 (5.27%)	0.046	1422 (5.25%)	34 (6.27%)	0.002
Paralysis	199 (0.73%)	208 (0.75%)	0.107	199 (0.73%)	19 (1.66%)	0.006
Rheumatoid arthritis	1463 (5.40%)	1519 (5.50%)	0.217	1463 (5.40%)	56 (10.33%)	0.012
HIV	15 (0.06%)	17 (0.06%)	0.127	15 (0.06%)	12 (0.37%)	0.000
MI	77 (0.28%)	78 (0.28%)	0.019	77 (0.28%)	11 (0.18%)	0.007

Variable	NSAIDs 72 h to 90 d					
	Before IPTW			After IPTW		
	Control	Intervention	SMD	Control	Intervention	SMD
Age, y, mean (SD)	51.57 (9.31)	51.84 (9.15)	0.167	51.57 (9.31)	53.10 (8.25)	0.009
Gender, woman, <i>n</i> (%)	15,187 (56.04%)	18,829 (57.19%)	0.131	15,187 (56.04%)	3642 (62.55%)	0.003
Comorbidities, <i>n</i> (%)						
CHF	884 (3.26%)	1073 (3.26%)	0.001	884 (3.26%)	189 (3.25%)	0.005
Diabetes	5594 (20.64%)	7031 (21.36%)	0.098	5594 (20.64%)	1437 (24.68%)	0.005
CPD	3907 (14.42%)	4921 (14.95%)	0.084	3907 (14.42%)	1014 (17.41%)	0.001
Tumors	24 (0.09%)	29 (0.09%)	0.001	24 (0.09%)	24 (0.09%)	0.002
PVD	1338 (4.94%)	1672 (5.08%)	0.036	1338 (4.94%)	334 (5.74%)	0.001
PUD	132 (0.49%)	165 (0.50%)	0.011	132 (0.49%)	33 (0.57%)	0.002
Stroke	382 (1.41%)	463 (1.41%)	0.002	382 (1.41%)	81 (1.39%)	0.000
Renal disease	287 (1.06%)	319 (0.97%)	0.052	287 (1.06%)	32 (0.55%)	0.013
Dementia	21 (0.08%)	27 (0.08%)	0.009	21 (0.08%)	21 (0.08%)	0.005
Liver disease	1422 (5.25%)	1768 (5.37%)	0.031	1422 (5.25%)	346 (5.94%)	0.007
Paralysis	199 (0.73%)	268 (0.81%)	0.050	199 (0.73%)	69 (1.18%)	0.001
Rheumatoid arthritis	1463 (5.40%)	2062 (6.26%)	0.202	1463 (5.40%)	599 (10.29%)	0.001
HIV	15 (0.06%)	20 (0.06%)	0.012	15 (0.06%)	15 (0.06%)	0.003
MI	77 (0.28%)	103 (0.31%)	0.029	77 (0.28%)	26 (0.45%)	0.005

Variable	NSAIDs 90 d to 1 y					
	Before IPTW			After IPTW		
	Control	Intervention	SMD	Control	Intervention	SMD
Age, y, mean (SD)	51.57 (9.31)	51.53 (9.28)	0.021	51.57 (9.31)	51.37 (9.19)	0.001
Gender, man, <i>n</i> (%)	15,187 (56.04%)	19,989 (57.40%)	0.124	15,187 (56.04%)	4802 (62.16%)	0.001
Comorbidities, <i>n</i> (%)						
CHF	884 (3.26%)	1137 (3.26%)	0.001	884 (3.26%)	253 (3.28%)	0.002
Diabetes	5594 (20.64%)	7191 (20.65%)	0.001	5594 (20.64%)	1597 (20.67%)	0.002
CPD	3907 (14.42%)	5251 (15.08%)	0.083	3907 (14.42%)	1344 (17.40%)	0.000
Tumors	24 (0.09%)	30 (0.09%)	0.004	24 (0.09%)	24 (0.09%)	0.002
PVD	1338 (4.94%)	1724 (4.95%)	0.003	1338 (4.94%)	386 (5.00%)	0.002
PUD	132 (0.49%)	174 (0.50%)	0.008	132 (0.49%)	42 (0.54%)	0.000
Stroke	382 (1.41%)	481 (1.38%)	0.011	382 (1.41%)	99 (1.28%)	0.001
Renal disease	287 (1.06%)	348 (1.00%)	0.027	287 (1.06%)	61 (0.79%)	0.004
Dementia	21 (0.08%)	31 (0.09%)	0.017	21 (0.08%)	11 (0.13%)	0.000
Liver disease	1422 (5.25%)	1917 (5.50%)	0.051	1422 (5.25%)	495 (6.41%)	0.000
Paralysis	199 (0.73%)	249 (0.71%)	0.010	199 (0.73%)	50 (0.65%)	0.002
Rheumatoid arthritis	1463 (5.40%)	2075 (5.96%)	0.107	1463 (5.40%)	612 (7.92%)	0.002
HIV	15 (0.06%)	21 (0.06%)	0.009	15 (0.06%)	15 (0.06%)	0.000
MI	77 (0.28%)	99 (0.28%)	0.000	77 (0.28%)	22 (0.28%)	0.002

Abbreviations: CHF, congestive heart failure; CPD, chronic pulmonary disease; HIV, human immunodeficiency virus; IPTW, inverse probability of treatment weighting; MI, myocardial infarction; NSAIDs, nonsteroidal anti-inflammatory drugs; PLF, posterior lumbar fusion; PUD, peptic ulcer disease; PVD, peripheral vascular disease; SMD, standardized mean difference.

Note: Cells with less than 11 patients were not reported or inferred per the data use agreement.

Table 3. Complication rates in PLF patients after NSAIDs use.

Complication	NSAIDs <72 h					
	N Control	N Intervention	OR/IRR	CI Lower	CI Upper	P
Readmission	47,754	873	0.883	0.631	1.237	0.470
Pseudoarthrosis and hardware failure	47,754	873	1.198	1.020	1.408	0.028
Wound complications	47,754	873	0.692	0.538	0.889	0.004
Length of stay	47,754	873	0.736	0.706	0.768	<0.001

Complication	NSAIDs 72 h to 90 d					
	N Control	N Intervention	OR/IRR	CI Lower	CI Upper	P
Readmission	47,754	10,526	1.011	0.962	1.063	0.666
Pseudoarthrosis and hardware failure	47,754	10,526	1.042	1.017	1.068	0.001
Wound complications	47,754	10,526	1.069	1.035	1.105	<0.001

Complication	NSAIDs 90 d to 1 y					
	N Control	N Intervention	OR/IRR	CI Lower	CI Upper	P
Readmission	47,754	13,633	1.020	0.990	1.051	0.186
Pseudoarthrosis and hardware failure	47,754	13,633	1.024	1.009	1.039	0.002
Wound complications	47,754	13,633	1.001	0.980	1.021	0.941

Abbreviations: IRR, incidence rate ratio; NSAIDs, nonsteroidal anti-inflammatory drugs; PLF, posterior lumbar fusion.

Note: Bold values indicate a significance at a Bonferroni-adjusted *P* value of <0.01.**Table 4.** Complication rates in PLF patients starting NSAIDs use <72 h with different dispensing intervals.

Complication	NSAIDs Days Dispensed (1–30 d)					
	N Control	N Intervention	OR	CI Lower	CI Upper	P
Readmission	47,754	452	0.803	0.494	1.306	0.376
Pseudoarthrodesis and hardware failure	47,754	452	1.229	0.981	1.538	0.072
Wound complications	47,754	452	0.571	0.391	0.832	0.004

Complication	NSAIDs Days Dispensed (31–90 d)					
	N Control	N Intervention	OR	CI Lower	CI Upper	P
Readmission	47,754	150	0.708	0.290	1.729	0.449
Pseudoarthrodesis and hardware failure	47,754	150	1.077	0.740	1.568	0.698
Wound complications	47,754	150	0.857	0.494	1.487	0.583

Complication	NSAIDs Days Dispensed (91–180 d)					
	N Control	N Intervention	OR	CI Lower	CI Upper	P
Readmission	47,754	82	1.053	0.385	2.880	0.919
Pseudoarthrodesis and hardware failure	47,754	82	1.805	0.998	3.266	0.051
Wound complications	47,754	82	1.026	0.513	2.053	0.941

Complication	NSAIDs Days Dispensed (181–365 d)					
	N Control	N Intervention	OR	CI Lower	CI Upper	P
Readmission	47,754	145	1.042	0.487	2.229	0.916
Pseudoarthrodesis and hardware failure	47,754	145	1.110	0.756	1.631	0.594
Wound complications	47,754	145	0.683	0.369	1.265	0.225

Complication	NSAIDs Days Dispensed (366–720 d)					
	N Control	N Intervention	OR	CI Lower	CI Upper	P
Readmission	47,754	44	1.503	0.465	4.857	0.496
Pseudoarthrodesis and hardware failure	47,754	44	0.907	0.467	1.762	0.773
Wound complications	47,754	44	0.833	0.298	2.328	0.727

Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; PLF, posterior lumbar fusion.

Note: Bold values indicate a significance at a Bonferroni-adjusted *P* value of ≤0.01.

Table 5. Complication rates in uncomplicated, single-level PLF patients after NSAIDs use.

Complication	NSAIDs <72 h					
	N Control	N Intervention	OR/IRR	CI Lower	CI Upper	P
Readmission	27,101	542	0.836	0.506	1.380	0.483
Pseudoarthrosis and hardware failure	27,101	542	1.068	0.882	1.294	0.500
Wound complications	27,101	542	0.839	0.599	1.175	0.308
Length of stay	27,101	542	0.757	0.715	0.801	<0.001

Complication	NSAIDs 72 h to 90 d					
	N Control	N Intervention	OR/IRR	CI Lower	CI Upper	P
Readmission	27,101	5823	1.029	0.954	1.109	0.462
Pseudoarthrosis and hardware failure	27,101	5823	1.048	1.015	1.082	0.004
Wound complications	27,101	5823	1.150	1.097	1.206	<0.001

Complication	NSAIDs 90 d to 1 y					
	N Control	N Intervention	OR/IRR	CI Lower	CI Upper	P
Readmission	27,101	7725	1.032	0.987	1.078	0.167
Pseudoarthrosis and hardware failure	27,101	7725	1.038	1.019	1.058	<0.001
Wound complications	27,101	7725	1.020	0.989	1.052	0.202

Abbreviations: IRR, incidence rate ratio; NSAIDs, nonsteroidal anti-inflammatory drugs; PLF, posterior lumbar fusion.

Note: Bold values indicate a significance at a Bonferroni-adjusted P value of <0.01.

Table 6. Complication rates in PLF patients starting NSAIDs use 72 h to 90 d with different dispensing intervals.

Complication	NSAIDs Days Dispensed (1–30 d)					
	N Control	N Intervention	OR	CI Lower	CI Upper	P
Readmission	47,754	3096	1.313	1.125	1.532	0.001
Pseudoarthrodesis and hardware failure	47,754	3096	0.984	0.906	1.070	0.712
Wound complications	47,754	3096	1.427	1.286	1.583	<0.001

Complication	NSAIDs Days Dispensed (31–90 d)					
	N Control	N Intervention	OR	CI Lower	CI Upper	P
Readmission	47,754	2074	0.899	0.723	1.119	0.342
Pseudoarthrodesis and hardware failure	47,754	2074	1.014	0.916	1.122	0.790
Wound complications	47,754	2074	1.115	0.973	1.278	0.117

Complication	NSAIDs Days Dispensed (91–180 d)					
	N Control	N Intervention	OR	CI Lower	CI Upper	P
Readmission	47,754	1616	0.916	0.717	1.170	0.483
Pseudoarthrodesis and hardware failure	47,754	1616	1.126	1.001	1.266	0.048
Wound complications	47,754	1616	0.953	0.810	1.122	0.564

Complication	NSAIDs Days Dispensed (181–365 d)					
	N Control	N Intervention	OR	CI Lower	CI Upper	P
Readmission	47,754	3408	0.893	0.751	1.062	0.201
Pseudoarthrodesis and hardware failure	47,754	3408	1.212	1.114	1.317	<0.001
Wound complications	47,754	3408	1.002	0.895	1.121	0.977

Complication	NSAIDs Days Dispensed (366–720 d)					
	N Control	N Intervention	OR	CI Lower	CI Upper	P
Readmission	47,754	332	0.972	0.578	1.634	0.914
Pseudoarthrodesis and hardware failure	47,754	332	1.228	0.945	1.596	0.124
Wound complications	47,754	332	1.173	0.845	1.629	0.341

Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; PLF, posterior lumbar fusion.

Note: Bold values indicate a significance at a Bonferroni-adjusted P value of ≤0.01.

Table 7. Complication rates in PLF patients starting NSAIDs use 90 d to 1 y with different dispensing intervals.

Complication	NSAIDs Days Dispensed (1–30 d)					
	N Control	N Intervention	OR	CI Lower	CI Upper	P
Readmission	47,754	7219	1.021	0.909	1.148	0.721
Pseudoarthrosis and hardware failure	47,754	7219	1.039	0.981	1.100	0.196
Wound complications	47,754	7219	0.952	0.878	1.033	0.239
Complication	NSAIDs Days Dispensed (31–90 d)					
	N Control	N Intervention	OR	CI Lower	CI Upper	P
Readmission	47,754	3314	1.083	0.921	1.273	0.333
Pseudoarthrosis and hardware failure	47,754	3314	1.096	1.009	1.190	0.030
Wound complications	47,754	3314	0.977	0.871	1.096	0.688
Complication	NSAIDs Days Dispensed (91–180 d)					
	N Control	N Intervention	OR	CI Lower	CI Upper	P
Readmission	47,754	1898	0.999	0.803	1.242	0.990
Pseudoarthrosis and hardware failure	47,754	1898	1.154	1.035	1.287	0.010
Wound complications	47,754	1898	1.064	0.920	1.229	0.405
Complication	NSAIDs Days Dispensed (181–365 d)					
	N Control	N Intervention	OR	CI Lower	CI Upper	P
Readmission	47,754	1193	1.358	1.069	1.725	0.012
Pseudoarthrosis and hardware failure	47,754	1193	1.104	0.964	1.264	0.152
Wound complications	47,754	1193	1.299	1.097	1.537	0.020

Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; PLF, posterior lumbar fusion.

Note: Bold values indicate a significance at a Bonferroni-adjusted P value of ≤ 0.01 .

Control vs 90 Days to 1 Year NSAIDs

While there was a notable association between NSAIDs use and pseudoarthrosis/hardware failure (1.024 [1.009, 1.039], $P = 0.002$), particularly when prescribed up to 90 (1.096 [1.009, 1.190], $P = 0.030$) or 180 days (1.154 [1.035, 1.287], $P = 0.010$) of NSAIDs, there was no association found with the rest of the tested outcomes (Table 7). Similarly, there was no significant association with readmissions (1.032 [0.987, 1.078], $P = 0.167$) or wound complications (1.020 [0.989, 1.052], $P = 0.202$) in patients who underwent single-level PLFs, but an association was found with pseudoarthrosis/hardware failure (1.038 [1.019, 1.058], $P < 0.001$; Table 5).

DISCUSSION

In this study, we utilized a national database to compare the outcomes of various postoperative NSAID administration windows in PLF patients. We analyzed a total of 47,754 patients and divided the cohort into those who received NSAIDs ≤ 72 hours after surgery, 72 hours to 90 days, or 90 days to 1 year—all compared with patients who did not receive NSAIDs. While we measured an association between NSAIDs 72 hours to 90 days and 90 days to 1 year postoperatively with increased pseudoarthrosis/hardware failure, the effect

size was the largest in the 72 hours to 90 days timeframe. Interestingly, receiving NSAIDs ≤ 72 hours after surgery was associated with decreased wound complications—particularly, when patients received short, ≤ 30 -day courses—as well as shorter LOS. Meanwhile, those who received NSAIDs 72 hours to 90 days after surgery had greater instances of wound complications, particularly when administered for ≤ 30 days. These findings were broadly similar in PLF patients who underwent uncomplicated, single-level fusions. Our results build upon existing literature by (1) comparing 3 timeframes within a single, confounder-adjusted cohort under consistent selection criteria, (2) extending beyond the commonly reported postoperative metric of nonunion by evaluating various outcomes, including wound complications, (3) analyzing the postoperative outcomes of various NSAIDs, (4) considering the effect of varying NSAIDs administration course lengths, and (5) sub-analyzing how associations may differ in a cohort of uncomplicated, single-level PLF patients.

To the best of our knowledge, there are only a few studies that have evaluated the impact of short-term postoperative NSAID administration (≤ 72 hours) on pseudoarthrosis outcomes.^{23–26} These studies have a limited focus on specific NSAIDs and exclusively measure the rates of pseudoarthrosis. To further complicate the interpretation of these studies, the results across them are mixed: 3 found

no association between ketorolac use ≤ 48 to 72 hours of surgery and pseudoarthrosis,^{23,24,26} while another study reported an increased association with pseudoarthrosis when ketorolac or fentanyl was administered ≤ 72 hours postoperatively.²⁵ The differences observed between these studies may result from variations in study populations and size, differently defined pseudoarthrosis, and the specific types and dosages of NSAIDs analyzed. NSAIDs administered 72 hours after surgery were associated with pseudoarthrosis in several studies.^{27–31} Our findings agree, further supporting the deleterious effects of long, ≥ 180 -day courses of NSAIDs when administered primarily 72 hours to 90 days after surgery, as shorter courses were not associated with these outcomes. To a much lesser extent, ≥ 90 -day NSAID courses started 90 days to 1 year after surgery were associated with pseudoarthrosis/hardware failure; however, the increased odds ratio was comparatively smaller, suggesting a reduced risk for these complications as the postoperative period lengthens.

Interestingly, we found decreased associations with wound complications and shorter LOS if NSAIDs were administered ≤ 72 hours after surgery, particularly, when administered ≤ 30 -day NSAIDs course, as longer medication courses were not associated with decreased wound complications or shorter LOS. This result aligns with prior studies; for instance, immediate postoperative ibuprofen does not increase bleeding in soft tissue surgeries;³² short, 4.5 to 13.5 days NSAIDs use following extremity wounds was associated with superior wound healing;³³ and aspirin had beneficial effects in treating chronic wounds by inhibiting cytokine release.³⁴ These studies, along with ours, suggest that in specific circumstances—particularly with short-term administrations—NSAIDs might not only fail to impede wound healing but could potentially enhance the process, especially in wounds that are prone to excessive inflammation.

While immediate postoperative administration might be associated with minimal or even beneficial effects on wound healing, NSAIDs used at other time points could lead to wound complications. For instance, Vadivelu et al found that prolonged NSAID use leads to impaired wound healing, especially in surgical patients,³⁵ and Schafer et al highlighted the risk of bleeding complications associated with long-term NSAID use, particularly in patients with coagulopathies or during perioperative period.³⁶ Our findings agree with these studies: patients who received NSAIDs 72 hours to 90 days postoperatively had a greater association with wound complications, even when only prescribed short, ≤ 30 -day medication courses. However, unlike these previous studies that identify associations between NSAID use and wound complications within a

specific time snapshot, our approach allows for a more nuanced understanding of how the timing and medication course lengths influence outcomes.

Clinical Implications

In light of these findings, clinicians should consider integrating the timing of NSAID administration into their perioperative management plans by evaluating the potential risks and benefits for individual patients. For both single- and multilevel fusion patients, administering NSAIDs within the first 72 hours after surgery may be safe and even beneficial for wound healing while also reducing hospital stays. LOS is influenced by hospital resources, workflows, therapy plans, patient compliance, and administrative processes;^{37–43} therefore, immediate, postoperative NSAID use may lead to reduced LOS by managing postoperative pain, improving mobility, expediting the start of physical therapy, and improving patient compliance—all of which are key in reducing complications, accelerating discharge, and efficiently utilizing health care resources. After 72 hours but before 90 days, caution is warranted, as both short and long courses of NSAIDs can negatively impact wound and bone healing. However, another safe window for NSAID use maybe after 90 days, as only the longest courses of NSAIDs were associated with pseudoarthrosis.

Limitations

While our study provides valuable insights into the effects of NSAID administration at various postoperative intervals on patient outcomes, there are limitations inherent to our analysis. These include the inability to control for all variables that might influence LOS and 30-day readmissions, such as hospital resource allocation, efficiency of care delivery, care transition planning, and insurance or administrative hurdles. Additionally, the reliance on administrative claims data limits our ability to establish causality, as the observed relationships are associative rather than causal. For example, NSAIDs may have been prescribed reactively to patients with higher baseline risks of complications, such as elevated pain or inflammation, suggesting the possibility of reverse causality. Our analysis also did not adjust for NSAID use prior to surgery nor could it differentiate the effects of various NSAID dosages due to dataset limitations. Future investigations should leverage institutional data sources, which could provide more control over such patient-specific factors, as well as prospective designs, including randomized controlled trials, to better evaluate causal relationships and refine our understanding of NSAID use on postoperative outcomes. Despite the limitations of this study, most of which are

inherent to the use of large patient databases, our research provides an initial exploration into the impacts of NSAID timing on postoperative outcomes in PLF patients.

CONCLUSIONS

Our study leverages a national payer's database to evaluate the impact of NSAID administration at different postoperative intervals in PLF patients. It identifies a link between long, ≥ 180 -day NSAID courses and increased pseudoarthrosis/hardware failure when administered 72 hours to 90 days—and to a lesser extent, 90 days to 1 year—after surgery. Patients who received NSAIDs ≤ 72 hours postoperatively, however, had lower associations with wound complications and decreased LOS. In contrast, those who received even short, ≤ 30 -day NSAID courses 72 hours to 90 days after surgery had a greater association with wound complications. These findings suggest that the timing of NSAID administration is crucial and warrants careful consideration in perioperative patient management. By analyzing a single patient population with consistent selection criteria across 3 distinct NSAID administration windows, our study facilitates a cross-comparison of postoperative outcomes as a function of time.

ACKNOWLEDGMENTS

Data for this project were accessed using the Stanford Center for Population Health Sciences Data Core. The PHS Data Core is supported by a National Institutes of Health National Center for Advancing Translational Science Clinical and Translational Science Award (UL1TR003142) and from Internal Stanford funding. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

REFERENCES

1. Youssef JA, Heiner AD, Montgomery JR, et al. Outcomes of posterior cervical fusion and decompression: a systematic review and meta-analysis. *Spine J*. 2019;19(10):1714–1729. doi:10.1016/j.spinee.2019.04.019
2. Martin BI, Mirza SK, Spina N, Spiker WR, Lawrence B, Brodke DS. Trends in lumbar fusion procedure rates and associated hospital costs for degenerative spinal diseases in the united states, 2004 to 2015. *Spine (Phila Pa 1976)*. 2019;44(5):369–376. doi:10.1097/BRS.0000000000002822
3. Weinstein JN, Lurie JD, Olson PR, Bronner KK, Fisher ES. United States' trends and regional variations in lumbar spine surgery: 1992-2003. *Spine (Phila Pa 1976)*. 2006;31(23):2707–2714. doi:10.1097/01.brs.0000248132.15231.fe
4. Ondeck NT, Bohl DD, Bovonratwet P, et al. Adverse events following posterior lumbar fusion: a comparison of spine surgeons perceptions and reported data for rates and risk factors. *Int J Spine Surg*. 2018;12(5):603–610. doi:10.14444/5074
5. Ghlichloo I, Gerriets V. Nonsteroidal anti-inflammatory drugs (NSAIDs). In: *StatPearls*. StatPearls Publishing; 2024.
6. Schug SA. Do nsoids really interfere with healing after surgery? *J Clin Med*. 2021;10(11):2359. doi:10.3390/jcm10112359
7. Davis TR, Ackroyd CE. Non-steroidal anti-inflammatory agents in the management of colles' fractures. *Br J Clin Pract*. 1988;42(5):184–189.
8. Burd TA, Hughes MS, Anglen JO. Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone non-union. *J Bone Joint Surg Br*. 2003;85(5):700–705. doi:10.1302/0301-620X.85B5.13970
9. Long J, Lewis S, Kuklo T, Zhu Y, Riew KD. The effect of cyclooxygenase-2 inhibitors on spinal fusion. *J Bone Joint Surg Am*. 2002;84(10):1763–1768. doi:10.2106/00004623-200210000-00004
10. Dimar JR II, Ante WA, Zhang YP, Glassman SD. The effects of nonsteroidal anti-inflammatory drugs on posterior spinal fusions in the rat. *Spine (Phila Pa 1986)*. 1996;21(16):1870–1876. doi:10.1097/00007632-199608150-00006
11. Martin GJ, Boden SD, Titus L. Recombinant human bone morphogenetic protein-2 overcomes the inhibitory effect of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), on posterolateral lumbar intertransverse process spine fusion. *Spine (Phila Pa 1976)*. 1999;24(21):2188–2193. doi:10.1097/00007632-199911010-00003
12. Al Farii H, Farahdel L, Frazer A, Salimi A, Bernstein M. The effect of nsoids on postfracture bone healing: a meta-analysis of randomized controlled trials. *OTA Int*. 2021;4(2):e092. doi:10.1097/OI9.0000000000000092
13. Drendel AL, Gorelick MH, Weisman SJ, Lyon R, Brouseau DC, Kim MK. A randomized clinical trial of ibuprofen versus acetaminophen with codeine for acute pediatric arm fracture pain. *Ann Emerg Med*. 2009;54(4):553–560. doi:10.1016/j.annemergmed.2009.06.005
14. Brattwall M, Turan I, Jakobsson J. Pain management after elective hallux valgus surgery: a prospective randomized double-blind study comparing etoricoxib and tramadol. *Anesth Analg*. 2010;111(2):544–549. doi:10.1213/ANE.0b013e3181e3d87c
15. Stanford Center for Population Health Sciences. MarketScan databases. *Redivis*. 2024. doi:10.57761/n5v8-0v21
16. Stuart EA, Lee BK, Leacy FP. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. *J Clin Epidemiol*. 2013;66(8 Suppl):S84–S90. doi:10.1016/j.jclinepi.2013.01.013
17. Neyman J, Pearson ES. On the use and interpretation of certain test criteria for purposes of statistical inference: part I. *Biom-etrika*. 1928;20A(1/2):175. doi:10.2307/2331945
18. Dunn OJ. Multiple comparisons among means. *J Am Stat Assoc*. 1961;56(293):52–64. doi:10.1080/01621459.1961.10482090
19. Streiner DL, Norman GR. Correction for multiple testing: is there a resolution? *Chest*. 2011;140(1):16–18. doi:10.1378/chest.11-0523
20. Dmitrienko A, D'Agostino R Sr. Traditional multiplicity adjustment methods in clinical trials. *Stat Med*. 2013;32(29):5172–5218. doi:10.1002/sim.5990
21. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. *Epidemiology*. 2009;20(4):512–522. doi:10.1097/EDE.0b013e3181a663cc

22. Hastie T, Tibshirani R, Friedman J. The elements of statistical learning. In: *The Elements of Statistical Learning*. New York: Springer; 2009:106–119. doi:10.1007/978-0-387-84858-7
23. Pradhan BB, Tatsumi RL, Gallina J, Kuhns CA, Wang JC, Dawson EG. Ketorolac and spinal fusion: does the perioperative use of ketorolac really inhibit spinal fusion? *Spine (Phila Pa 1976)*. 2008;33(19):2079–2082. doi:10.1097/BRS.0b013e31818396f4
24. Sucato DJ, Lovejoy JF, Agrawal S, Elerson E, Nelson T, McClung A. Postoperative ketorolac does not predispose to pseudoarthrosis following posterior spinal fusion and instrumentation for adolescent idiopathic scoliosis. *Spine (Phila Pa 1976)*. 2008;33(10):1119–1124. doi:10.1097/BRS.0b013e31816f6a2a
25. Park S-Y, Moon S-H, Park M-S, Oh K-S, Lee H-M. The effects of ketorolac injected via patient controlled analgesia post-operatively on spinal fusion. *Yonsei Med J*. 2005;46(2):245–251. doi:10.3349/ymj.2005.46.2.245
26. Vitale MG, Choe JC, Hwang MW, et al. Use of ketorolac tromethamine in children undergoing scoliosis surgery. An analysis of complications. *Spine J*. 2003;3(1):55–62. doi:10.1016/s1529-9430(02)00446-1
27. Glassman SD, Rose SM, Dimar JR, Puno RM, Campbell MJ, Johnson JR. The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. *Spine (Phila Pa 1976)*. 1998;23(7):834–838. doi:10.1097/00007632-199804010-00020
28. Lumawig JMT, Yamazaki A, Watanabe K. Dose-dependent inhibition of diclofenac sodium on posterior lumbar interbody fusion rates. *Spine J*. 2009;9(5):343–349. doi:10.1016/j.spinee.2008.06.455
29. Lindsay SE, Philipp T, Ryu WHA, Wright C, Yoo J. Nonsteroidal anti-inflammatory drugs in the acute post-operative period are associated with an increased incidence of pseudarthrosis, hardware failure, and revision surgery following single-level spinal fusion. *Spine (Phila Pa 1976)*. 2023;48(15):1057–1063. doi:10.1097/BRS.0000000000004695
30. Deguchi M, Rapoff AJ, Zdeblick TA. Posterolateral fusion for isthmia spondylolisthesis in adults: analysis of fusion rate and clinical results. *J Spinal Disord*. 1998;11(6):459–464.
31. Li Q, Zhang Z, Cai Z. High-dose ketorolac affects adult spinal fusion: a meta-analysis of the effect of perioperative nonsteroidal anti-inflammatory drugs on spinal fusion. *Spine (Phila Pa 1976)*. 2011;36(7):E461–E468. doi:10.1097/BRS.0b013e3181df163
32. Kelley BP, Bennett KG, Chung KC, Kozlow JH. Ibuprofen may not increase bleeding risk in plastic surgery: a systematic review and meta-analysis. *Plast Reconstr Surg*. 2016;137(4):1309–1316. doi:10.1097/PRS.0000000000002027
33. Lisboa FA, Bradley MJ, Hueman MT, et al. Nonsteroidal anti-inflammatory drugs may affect cytokine response and benefit healing of combat-related extremity wounds. *Surgery*. 2017;161(4):1164–1173. doi:10.1016/j.surg.2016.10.011
34. Darby IA, Weller CD. Aspirin treatment for chronic wounds: potential beneficial and inhibitory effects. *Wound Repair Regen*. 2017;25(1):7–12. doi:10.1111/wrr.12502
35. Vadivelu N, Kai AM, Kodumudi V, Sramcik J, Kaye AD. The opioid crisis: a comprehensive overview. *Curr Pain Headache Rep*. 2018;22(3):16. doi:10.1007/s11916-018-0670-z
36. Schafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. *Am J Med*. 1999;106(5B):25S–36S. doi:10.1016/s0002-9343(99)00114-x
37. Leng X, Zhang Y, Wang G, et al. An enhanced recovery after surgery pathway: LOS reduction, rapid discharge and minimal complications after anterior cervical spine surgery. *BMC Musculoskelet Disord*. 2022;23(1):252. doi:10.1186/s12891-022-05185-0
38. Shields LBE, Clark L, Glassman SD, Shields CB. Decreasing hospital length of stay following lumbar fusion utilizing multidisciplinary committee meetings involving surgeons and other caretakers. *Surg Neurol Int*. 2017;8:5. doi:10.4103/2152-7806.198732
39. Kim JH, Shin YS. Discharge transition experience for lumbar fusion patients: a qualitative study. *J Neurosci Nurs*. 2021;53(6):228–232. doi:10.1097/JNN.0000000000000616
40. Gonçalves-Bradley DC, Lannin NA, Clemson LM, Cameron ID, Shepperd S. Discharge planning from hospital. *Cochrane Database Syst Rev*. 2016;2016(1):CD000313. doi:10.1002/14651858.CD000313.pub5
41. Dasenbrock HH, Clarke MJ, Witham TF, Sciubba DM, Gokaslan ZL, Bydon A. The impact of provider volume on the outcomes after surgery for lumbar spinal stenosis. *Neurosurgery*. 2012;70(6):1346–1353. doi:10.1227/NEU.0b013e318251791a
42. Soffin EM, Beckman JD, Tseng A, et al. Enhanced recovery after lumbar spine fusion: a randomized controlled trial to assess the quality of patient recovery. *Anesthesiology*. 2020;133(2):350–363. doi:10.1097/ALN.0000000000003346
43. Dosselman LJ, Pernik MN, El Tecle N, et al. Impact of insurance provider on postoperative hospital length of stay after spine surgery. *World Neurosurg*. 2021;156:e351–e358. doi:10.1016/j.wneu.2021.09.065

Funding: This study was conducted without any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of Conflicting Interests: The authors declare no conflicts of interest related to this work. They have no financial, personal, or institutional relationships that could be perceived as influencing the content of this manuscript.

Corresponding Author: Aneysis D. Gonzalez-Suarez, Department of Neurosurgery, Stanford University School of Medicine, 300 Pasteur Dr, R281, Stanford, CA 94305-5327, USA; adg52@stanford.edu

Published 27 March 2025

Copyright © 2025 ISASS. The IJSS is an open access journal following the Creative Commons Licensing Agreement CC BY-NC-ND. To learn more or order reprints, visit <http://ijssurgery.com>.